)
Hyderabad-based bio-pharmaceutical company Suven Life Sciences Limited today said it secured patents in four countries to one of their new chemical entity (NCE) targeted for treating degenerative brain diseases through a new mechanism of action.
"The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders," the company said in a statement.
The patents for the said NCE were issued in Australia, Canada, Japan and New Zealand, it said. With these new patents, Suven has a total of 20 granted patents from Australia, 17 from Canada, 15 from Japan and 22 from New Zealand, according to the press release.
